completed

 Despite the use of aspirin, there is still a risk of ischaemic events after percutaneous coronary intervention (PCI).

We aimed to find out whether, in addition to aspirin, pretreatment with clopidogrel followed by long-term therapy after PCI is superior to a strategy of no pretreatment and short-term therapy for only 4 weeks after PCI.

The objective of the PCI-CURE study was to determine if, in addition to aspirin, pretreatment with clopidogrel followed by long-term therapy after a patient undergoes percutaneous coronary intervention (PCI) is superior to a strategy of no pretreatment and short-term therapy for only four weeks after PCI.

Patients with non-ST-elevation acute coronary syndrome undergoing PCI in our CURE study were randomly assigned double-blind treatment with clopidogrel or placebo.

Primary endpoint:

A composite of cardiovascular death, myocardial infarction, or urgent target-vessel revascularisation within 30 days of PCI.

We concluded that in patients with acute coronary syndrome receiving aspirin, a strategy of clopidogrel pretreatment followed by long-term therapy is beneficial in reducing major cardiovascular events, compared with placebo.

Study Type

Interventional - Drug

Study Design

Randomized double-blind

NO. of Countries

28

NO. of Sites

482

NO. of Participants

2658

Study Period

1998 - 2001

Sponsor

Sanofi

Back To Top